tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TVTX Stock Latest News

Optimistic Buy Rating for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Positioning
RatingsOptimistic Buy Rating for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Positioning
16d ago
TVTX
Positive Outlook for Travere Therapeutics: FILSPARI’s Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk
PremiumRatings
Positive Outlook for Travere Therapeutics: FILSPARI’s Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk
19d ago
TVTX
Travere Therapeutics announces data from Phase 3 DUPLEX study of FILSPARI
PremiumThe Fly
Travere Therapeutics announces data from Phase 3 DUPLEX study of FILSPARI
19d ago
TVTX
Travere Therapeutics price target raised to $35 from $26 at Piper Sandler
PremiumThe Fly
Travere Therapeutics price target raised to $35 from $26 at Piper Sandler
21d ago
TVTX
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
PremiumRatings
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
22d ago
TVTX
Travere Therapeutics’ Strong Quarter and Future Prospects
PremiumCompany AnnouncementsTravere Therapeutics’ Strong Quarter and Future Prospects
25d ago
TVTX
Citi ups Travere target, opens ‘upside 90-day catalyst watch’
Premium
The Fly
Citi ups Travere target, opens ‘upside 90-day catalyst watch’
26d ago
TVTX
Travere Therapeutics price target raised to $40 from $30 at TD Cowen
Premium
The Fly
Travere Therapeutics price target raised to $40 from $30 at TD Cowen
26d ago
TVTX
Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
PremiumRatings
Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
26d ago
TVTX
Travere Therapeutics Reports Strong Q3 2025 Growth
PremiumCompany Announcements
Travere Therapeutics Reports Strong Q3 2025 Growth
26d ago
TVTX
Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
PremiumRatings
Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
26d ago
TVTX
Closing Bell Movers: Amazon soars to all-time highs on earnings
PremiumThe Fly
Closing Bell Movers: Amazon soars to all-time highs on earnings
26d ago
Z
EW
Travere Therapeutics reports Q3 EPS 29c, consensus (9c)
PremiumThe FlyTravere Therapeutics reports Q3 EPS 29c, consensus (9c)
26d ago
TVTX
Is TVTX a Buy, Before Earnings?
Premium
Pre-Earnings
Is TVTX a Buy, Before Earnings?
29d ago
TVTX
Travere Therapeutics’ Sparsentan Study: A Potential Game-Changer in Kidney Transplant Treatment
Premium
Company Announcements
Travere Therapeutics’ Sparsentan Study: A Potential Game-Changer in Kidney Transplant Treatment
29d ago
TVTX
Travere Therapeutics Advances Sparsentan Study in Pediatric Kidney Diseases
PremiumCompany Announcements
Travere Therapeutics Advances Sparsentan Study in Pediatric Kidney Diseases
29d ago
TVTX
Travere Therapeutics Advances Phase 3 Study for Rare Genetic Disorder Treatment
PremiumCompany Announcements
Travere Therapeutics Advances Phase 3 Study for Rare Genetic Disorder Treatment
29d ago
TVTX
Travere Therapeutics’ Study on Homocystinuria: A Closer Look at the ACAPPELLA Study
PremiumCompany Announcements
Travere Therapeutics’ Study on Homocystinuria: A Closer Look at the ACAPPELLA Study
29d ago
TVTX
Travere Therapeutics to present abstracts at ASN Kidney Week
PremiumThe Fly
Travere Therapeutics to present abstracts at ASN Kidney Week
1M ago
TVTX
Travere Therapeutics price target lowered to $35 from $45 at Evercore ISI
PremiumThe FlyTravere Therapeutics price target lowered to $35 from $45 at Evercore ISI
2M ago
TVTX
FILSPARI Positioned as Foundational Therapy for IgAN Following KDIGO Guidelines and PROTECT Study Validation
Premium
Ratings
FILSPARI Positioned as Foundational Therapy for IgAN Following KDIGO Guidelines and PROTECT Study Validation
2M ago
TVTX
Target initiated, Nike upgraded: Wall Street’s top analyst calls
Premium
The Fly
Target initiated, Nike upgraded: Wall Street’s top analyst calls
2M ago
DG
HD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >